In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Cidara Therapeutics Inc (NASDAQ: CDTX) closed at $24.28 in the last session, down -5.53% from day before closing price of $25.70. In other words, the price has decreased by -$5.53 from its previous closing price. On the day, 0.16 million shares were traded. CDTX stock price reached its highest trading level at $25.85 during the session, while it also had its lowest trading level at $24.1201.
Ratios:
We take a closer look at CDTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 3.87 and its Current Ratio is at 3.87. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citizens JMP on March 12, 2025, initiated with a Mkt Outperform rating and assigned the stock a target price of $46.
On December 13, 2024, RBC Capital Mkts started tracking the stock assigning a Outperform rating and target price of $34.RBC Capital Mkts initiated its Outperform rating on December 13, 2024, with a $34 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 11 ’25 when Ward Shane sold 1,664 shares for $21.96 per share. The transaction valued at 36,542 led to the insider holds 14,674 shares of the business.
Tari Leslie sold 1,773 shares of CDTX for $38,940 on Mar 11 ’25. The CHIEF SCIENTIFIC OFFICER now owns 16,215 shares after completing the transaction at $21.96 per share. On Sep 11 ’24, another insider, Sandison Taylor, who serves as the Chief Medical Officer of the company, sold 924 shares for $11.64 each. As a result, the insider received 10,752 and left with 23,067 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDTX now has a Market Capitalization of 314906752 and an Enterprise Value of 149430304. For the stock, the TTM Price-to-Sale (P/S) ratio is 1049.70 while its Price-to-Book (P/B) ratio in mrq is 2.09. Its current Enterprise Value per Revenue stands at 494.802 whereas that against EBITDA is -1.386.
Stock Price History:
The Beta on a monthly basis for CDTX is 0.86, which has changed by 1.0628717 over the last 52 weeks, in comparison to a change of 0.09362543 over the same period for the S&P500. Over the past 52 weeks, CDTX has reached a high of $28.42, while it has fallen to a 52-week low of $10.14. The 50-Day Moving Average of the stock is 15.74%, while the 200-Day Moving Average is calculated to be 34.63%.
Shares Statistics:
According to the various share statistics, CDTX traded on average about 152.95K shares per day over the past 3-months and 215640 shares per day over the past 10 days. A total of 12.21M shares are outstanding, with a floating share count of 7.68M. Insiders hold about 40.80% of the company’s shares, while institutions hold 53.73% stake in the company. Shares short for CDTX as of 1745971200 were 452539 with a Short Ratio of 2.96, compared to 1743379200 on 470336. Therefore, it implies a Short% of Shares Outstanding of 452539 and a Short% of Float of 3.61.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The dynamic stock of Cidara Therapeutics Inc (CDTX) is currently attracting attention from 5.0 analysts actively involved in rating its market status.The consensus estimate for the next quarter is -$1.85, with high estimates of -$1.24 and low estimates of -$2.8.
Analysts are recommending an EPS of between -$5.58 and -$9.31 for the fiscal current year, implying an average EPS of -$7.38. EPS for the following year is -$8.02, with 5.0 analysts recommending between -$5.3 and -$10.49.
